<SEC-DOCUMENT>0001144204-14-049798.txt : 20140814
<SEC-HEADER>0001144204-14-049798.hdr.sgml : 20140814
<ACCEPTANCE-DATETIME>20140814111355
ACCESSION NUMBER:		0001144204-14-049798
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140814
DATE AS OF CHANGE:		20140814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		141040518

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v386498_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (date of earliest event reported):
<B>August 14, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><B>01-12584</B></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><B>13-3808303</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Ste. 412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD
20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-top: black 1pt solid; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Address
of principal executive offices and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>617 Detroit Street, Ste. 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ann Arbor, MI
48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-top: black 1pt solid; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Mailing
Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Registrant&rsquo;s
telephone number including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name and Former Address)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2014, Synthetic Biologics,
Inc., a Nevada corporation, (the &ldquo;Registrant&rdquo;) issued the attached press release that included financial information
for the quarter ended June 30, 2014. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any
of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01&nbsp;&nbsp;Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">(d)&nbsp;&nbsp;</TD>
    <TD STYLE="width: 97%; text-align: justify">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc., dated August 14, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 49%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 14, 2014</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">(d)&nbsp;&nbsp;</TD>
    <TD STYLE="width: 97%">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc., dated August 14, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v386498_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48pt; width: 243.75pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics Reports Second Quarter
2014 Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Expanded Data from Phase II MS
Trial to be Released Next Month; Plans on Course to Advance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>C. difficile and
C-IBS Programs into the Clinic During 2014 --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Conference Call Today, August 14,
2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>--</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, August 14, 2014 &ndash;</B> </FONT>Synthetic Biologics, Inc.<FONT STYLE="color: windowtext"> (NYSE MKT: SYN), </FONT>a developer
of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases<FONT STYLE="color: windowtext">,
today reported financial results for the three and six months ended June 30, 2014, and provided an operational progress update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jeffrey Riley, CEO of Synthetic Biologics,
stated, &ldquo;We have accomplished key goals in all of our pipeline programs, further built infrastructure, including GMP manufacturing
resources to support these activities, and filed new patent applications covering our C-IBS and Pertussis programs, as well as
in the Trimesta program for multiple sclerosis (MS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Of particular note, I am pleased
to report that significant progress has been made in further analysis of the clinical outcomes in the Phase II MS study of Trimesta
since topline results were presented in April 2014. It is important to emphasize that patients treated with Trimesta benefited
from the dual mode of action of the drug, including the anti-inflammatory effects that improve relapse rate, as well as the potential
neuroprotective effects that improve disability and cognition measures. Additional MRI analyses are ongoing to evaluate changes
in the brain that correlate with the improvements seen in clinical outcome. The expanded data from the trial continues to build
our confidence in the high value of this program for patients with MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;In addition, we have completed plans
to file INDs and initiate clinical trials this year for our <I>C. difficile</I> and C-IBS programs, both of which are expected
to report topline Phase II data in mid-2015. We also have plans to file an IND and start Phase I testing during the first half
of next year of our novel monoclonal antibody cocktail as a first-in-class candidate for the prevention and treatment of Pertussis
(whooping cough).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley added that near-term calendar
events include a planned September 12<SUP>th</SUP> presentation at the 2014 Joint Americas and European Committees for Treatment
and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston of additional Trimesta MS data, including important new
findings in cognitive function, and a Company-sponsored IBS Investor Day planned for September 16<SUP>th</SUP> in NYC which will
include clinical presentations by Mark Pimentel, M.D., FRCP(C) of Cedars-Sinai Medical Center, the lead investigator of our 505(b)(2)
compound, SYN-010 for constipation-predominant irritable bowel syndrome (C-IBS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Three and Six Months Ended June 30, 2014 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1.8 million and $2.9 million for the three and six months ended June 30, 2014, respectively, compared to $1.3 million and $2.4
million for the same periods in 2013. These increases of 44% and 23%, respectively, are primarily the result of supplemental compensation
granted by the Board of Directors to executive officers and increased stock-based compensation expense. Non-cash charges related
to stock-based compensation were $645,000 and $899,000 for the three and six months ended June 30, 2014, respectively, compared
to $298,000 and $652,000 for the same periods in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $2.8 million and $5.6 million for the three and six months ended June 30, 2014, respectively, compared to $1.2 million and $2.3
million, for the same periods in 2013. These increases of 136% and 139%, respectively, are primarily the result of increased program
costs associated with expanded research, development and manufacturing activities within our anti-infective pipeline, including
the Company&rsquo;s <I>C. diff</I>, C-IBS and Pertussis programs. Non-cash charges related to stock-based compensation were $210,000
and $318,000 for the three and six months ended June 30, 2014, respectively, compared to $109,000 and $212,000 for the same period
in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $95,000 and $96,000 for
the three and six months ended June 30, 2014, respectively, compared to other expense of $36,000 and $24,000 for the same periods
in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Thursday, August 14, 2014, at 8:30 am EDT, during which Mr. Riley will provide an operational update and C.
Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the three and six
months ended June 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested parties should call 1-877-870-4263
(U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-317-0790 (International), fifteen minutes before the start of the
call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question &amp; Answer Session.
The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=100224. If you are unable to participate
during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=100224,
for 30 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Clinical Programs Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Relapsing-Remitting Multiple Sclerosis
(RRMS) &ndash; Trimesta&trade; (oral estriol)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trimesta's differentiated dual mechanism
of action, combined with the convenience of once-daily oral dosing, potentially make it an ideal therapy to address this underserved
$14.1 billion worldwide market<SUP>i</SUP>. Based on previous research findings,<SUP>ii</SUP> Trimesta may offer both anti-inflammatory
and neuro-protective benefits for patients with MS. Available MS therapies demonstrate anti-inflammatory or immunomodulatory effects,
but in general are not considered neuro-protective agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><I>MS Operational
Highlights and Upcoming Milestones:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">At the American Academy of Neurology annual meeting in April, lead investigator Rhonda Voskuhl,
M.D. from the University of California, Los Angeles (UCLA) David Geffen School of Medicine, presented positive initial topline
efficacy and safety results from the investigator-initiated Phase II trial evaluating adjunctive Trimesta in women with RRMS.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The study was a Phase II comparing Trimesta plus Copaxone&reg; to Copaxone&reg; alone as the active
control arm in total of 158 women with RRMS.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Efficacy results far surpassed the investigator&rsquo;s expectations, meeting the pre-specified
endpoint of the study protocol by demonstrating a statistically significant decrease in relapse rate after 12 months of therapy,
for which the study was powered to achieve statistical significance, and a clinically meaningful reduction in relapse rate after
24 months of therapy, powered for trend as a pre-specified goal of the trial.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Trimesta in combination was also safe and well tolerated by women in the study.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The study also demonstrated statistically significant and clinically relevant improvement in cognitive
scores at 12 months of therapy, which is of high importance for MS specialists and patients and is believed to be the result of
Trimesta's unique neuroprotective effect.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Since the presentation of the initial topline results from the trial, significant additional analyses
have been performed on various clinical outcome measures, as well as important parameters from ongoing analysis of MRI brain scans.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Dr. Voskuhl is scheduled to present some of the expanded data from this additional clinical outcome
analyses, including more detailed results on cognitive and disability measures, at the ACTRIMS-ECTRIMS meeting in Boston on September
12, 2014.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A separate Phase II trial focused exclusively
on cognition utilizing Trimesta with a variety of currently marketed MS drugs, including Copaxone&reg;, Avonex&reg;, Betaseron&reg;,
Extavia&reg;, Rebif&reg;, Gilenya&reg;, Aubagio&reg; and Tecfidera&reg;, is currently enrolling patients at four sites in the United
States.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Synthetic Biologics continues discussions to attract a strategic partner to accelerate development
of this innovative therapy for relapsing-remitting MS in women.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prevention of <I>C. difficile (C. diff.)</I>
Infections &ndash; SYN-004 Oral Enzyme</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-004, Synthetic Biologics&rsquo; lead
anti-infective product candidate, is believed to be the first and only therapy designed to neutralize intravenous (IV) antibiotics
in the gut. It is intended to protect and maintain the balance of bacterial flora in the gastrointestinal tract, to potentially
prevent the devastating effects of <I>C. diff</I>. The U.S. Centers for Disease Control and Prevention (CDC) has classified <I>C.
diff</I> as an &ldquo;urgent public health threat&rdquo;, surpassing Methicillin-resistant<I> Staphylococcus aureus</I> (MRSA)
as the number one hospital-acquired infection in the United States. <I>C. diff</I> is a multidrug-resistant bacterium that infects
1.1 million U.S. patients annually,<SUP>iii</SUP> and 30,000 patients die with a <I>C. diff</I> infection annually<SUP>iv</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>C. diff Operational
Highlights and Upcoming Milestones:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completion of final preclinical toxicology
study and subsequent filing of an Investigational New Drug (IND) application in anticipation of human clinical development expected
in the upcoming quarter.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiation of Phase Ia and Ib clinical
trials expected in the fourth quarter of 2014, with preliminary topline data expected by year-end 2014. A Phase II efficacy study
is expected to begin in the first half of 2015.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical drug manufacturing of SYN-004
in accordance with GMP guidelines is currently underway pursuant to execution of an agreement with Evonik.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>C. diff</I> Clinical Advisory Board
(CAB) comprised of industry leaders Mark Wilcox, M.D., (Chairman), Curtis Donskey, M.D., Ciar&aacute;n Kelly, M.D. and Tom Louie,
M.D., formed to support clinical development of SYN-004.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical microbiome study in collaboration
with Enterome Bioscience expected to begin in second half of 2014.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
&ndash; SYN-010 Oral Compound</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Mark Pimentel of Cedars-Sinai Medical
Center (CSMC), led the investigational team whose critical discoveries into the underlying cause of gas, pain and constipation
associated with C-IBS established the foundation of Synthetic Biologics&rsquo; C-IBS program, and are the basis for developing
an oral treatment to reduce the impact of methane-producing organisms on conditions such as C-IBS. Of the 40 million IBS patients
in the United States<SUP>v</SUP>, approximately 13.2 million have C-IBS<SUP>vi</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><I>C-IBS
Operational Highlights and Upcoming Milestones:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiation of a Phase II dose-discovery
and proof-of-mechanism clinical trial of SYN-010 in C-IBS expected during the second half of 2014 under a corporate IND, with topline
data expected mid-2015.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">C-IBS CAB formed with Dr. Mark Pimentel
as Chairman; in process of adding other prominent thought leaders and researchers in the field of C-IBS.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Synthetic Biologics to host an IBS investor
day in New York on September 16, 2014, to provide an overview of the clinical development strategy for SYN-010, with Dr. Pimentel
as keynote speaker.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pertussis (Whooping Cough) &ndash; SYN-005
Monoclonal Antibody (mAb) Combination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-005, a unique combination of two humanized
antibodies designed to target and neutralize pertussis toxin, a major cause of Pertussis-mediated infant morbidity and mortality,
is being developed under an exclusive channel collaboration with Intrexon Corporation (NYSE: XON), and Synthetic Biologics&rsquo;
academic collaborator, The University of Texas at Austin. Despite widespread vaccination, Pertussis rates in the United States
continue to rise steadily, and according to the World Health Organization, <I>B. pertussis</I> infection causes an estimated 300,000
deaths worldwide each year, primarily among young, unvaccinated infants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Pertussis Operational
Highlights and Upcoming Milestones:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Positive preclinical data reported from
two non-human primate studies, supporting the association of SYN-005 with favorable decreases in white blood cell counts within
two days and achievement of nearly normal levels within one week of treatment with SYN-005. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Research was highlighted last month at a Gordon Research Conference on Microbial Toxins and Pathogenicity
by Synthetic Biologics&rsquo; academic collaborator at The University of Texas at Austin, Jennifer Maynard, Ph.D.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Dr. Maynard to present Synthetic Biologics' SYN-005 mAb combination for the treatment of Pertussis
in an oral presentation at the 54<SUP>th</SUP> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September
7<SUP>th</SUP> in Washington D.C.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filing of IND and initiation of a Phase
I clinical trial is expected during the first half of 2015. Topline data is expected within approximately 90<B> </B>days of the
start of the trial, after which a Phase II trial is planned, with topline results expected in the second half of 2015.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orphan Drug designation request submitted
for SYN-005 for the treatment of Pertussis.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intend to initiate cGMP manufacturing
of SYN-005 to support clinical studies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley concluded, &ldquo;We look forward
to Dr. Voskuhl&rsquo;s presentation at the ACTRIMS-ECTRIMS meeting in September. Dr. Voskuhl is expected to provide details about
the significant clinical outcome measures including relapse rate, disability, and cognition measures evaluated in this compelling
Phase II trial. We believe the unique and differentiated anti-inflammatory, as well as neuroprotective benefits of Trimesta, have
the potential to provide a new opportunity to be an ideal added or standalone oral therapy to address significant unmet needs for
women affected by this progressive, debilitating condition.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens
that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora
from the effects of IV antibiotics for the prevention of <I>Clostridium difficile (C. difficile)</I> infection, an oral treatment
to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal
antibodies for the treatment of Pertussis and <I>Acinetobacter</I> infections, and a biologic targeted at the prevention and treatment
of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting
multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copaxone&reg; is a registered trademark
of Teva Pharmaceutical Industries Ltd. Avonex&reg; is a registered trademark of Biogen Idec. Rebif&reg; is a registered trademark
of EMD Serono, Inc. or its affiliates. Betaseron<B><I>&reg; </I></B>is a registered trademark of Bayer HealthCare Pharmaceuticals.
Extavia<B><I>&reg; </I></B>is a registered trademark of Novartis AG. Gilenya<B><I>&reg; </I></B>is a registered trademark of Novartis
AG. Aubagio&reg; is a registered trademark of Genzyme Corporation. Tecfidera&reg; is a registered trademark of Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding advancing Synthetic Biologics&rsquo;
clinical programs, Synthetic Biologics&rsquo; opportunities and its position in the infectious disease market, the intended benefits
of the products being developed, the anticipated timing and results of the Synthetic Biologics&rsquo; clinical trials, including
the expected initiation date of the Phase Ia and Ib clinical trial for SYN-004, the date of release of topline data from the trial,
the Phase II efficacy trial for SYN -004 and the microbiome study commencement date, expected date of the initiation of the Phase
II clinical trial for SYN-010 and release of topline data, expected filing date of an IND, initiation of a Phase I clinical trial
and release of topline data for SYN-005, and the expected size of the future market for sales of Synthetic Biologics&rsquo; therapies.
The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from
those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from those reflected in Synthetic Biologics&rsquo; forward-looking statements include, among others, a failure to receive the necessary
regulatory approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo;
clinical trials, and those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure
of Synthetic Biologics&rsquo; clinical trials to receive anticipated funding, a failure of Synthetic Biologics&rsquo; products
for the treatment of infectious diseases to be successfully developed or commercialized, Synthetic Biologics&rsquo; inability to
maintain its licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize
products and other factors described in Synthetic Biologics&rsquo; report on Form 10-K for the year ended December 31, 2013 and
any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information,
future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics: Kris Maly, VP, Corporate
Communication, (734) 332-7800, info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media: Wendy Emanuel, Wellspring Communications,
Inc., (773) 255-9580, wendy@wellspringcom.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors: Joshua Drumm, Ph.D., Tiberend
Strategic Advisors, Inc., (212) 375-2664, jdrumm@tiberend.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="8" STYLE="font-size: 10pt; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="8" STYLE="font-size: 10pt; text-align: center"><B>(in thousands, except share and per share amounts)</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2013</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Audited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">7,843</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">14,625</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,389</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,591</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,289</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,232</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Synthetic Biologics, Inc. and subsidiaries equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,057</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,289</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the six months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,814</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,936</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,380</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,837</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,203</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,554</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,321</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,651</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,461</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,490</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,701</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,651</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,461</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,490</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,701</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other income (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(46</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income (Expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,556</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,394</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,725</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to <BR>Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,556</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,497</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,394</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,725</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.11</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,453,528</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,654,414</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,348,153</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,628,051</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"># # #</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________<SUP>&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>i</SUP></TD><TD STYLE="text-align: justify">Credit Suisse. Multiple Sclerosis-Evolution or Revolution
Report. March 18, 2013.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>ii</SUP></TD><TD STYLE="text-align: justify">Sicotte, NL, et al. Treatment of Multiple Sclerosis with
the Pregnancy Hormone Estriol. Ann Neurol 2002; 52:421&ndash;428.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>iii</SUP></TD><TD STYLE="text-align: justify">This information is an estimate derived from the use
of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year
2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>iv</SUP></TD><TD STYLE="text-align: justify">U.S. Department of Health &amp; Human Services. Agency
for Healthcare Research and Quality. January 25, 2012. http://www.ahrq.gov/news/nn/nn012512.htm Accessed: September 30, 2013.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>v</SUP></TD><TD STYLE="text-align: justify">GlobalData EPI Database Report &ndash; Prevalent Cases,
March 2014.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>vi</SUP></TD><TD STYLE="text-align: justify">American College of Gastroenterology website: http://patients.gi.org/topics/irritable-bowel-syndrome/#tabs3
Accessed: May 14, 2014.</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_X0O$17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````H@```,X`#T)````G
M$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,3(Z
M,3@@,3`Z,C@Z,34```.@`0`#`````0`!``"@`@`$`````0```D^@`P`$````
M`0```8H`````````!@$#``,````!``8```$:``4````!```!'`$;``4````!
M```!)`$H``,````!``(```(!``0````!```!+`("``0````!```*CP``````
M``!(`````0```$@````!_]C_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#
M`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``?`*`#`2$``A$!`Q$!_\0`'P``
M`04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0`
M``%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!
M`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W>\OH+&,-,QRQ
MPJJ,EC["JIU"^DB,EOIC.,C:'E"$CUZ'V_.HJ.48-Q5WV*@HN24G9!_:WDJS
M7ME<6JHNYG(#IU`QE23W]*O0SQ7,2RP2I+&WW71@P/XBBE.4X\SBUZE5*?)L
M[KNB2L'Q5XLT_P`):<EU>[Y))6*PP1XWR'OU[#C)[9'J!5F9S5O\47MK^WM_
M$7AR^T:.Y($4TK$KG(R3N5<`9&<9QZ5LZ'XV@U7Q%>Z#=V4FGZC;=(I7SYH'
M4KP,\8(]0<C@4`5;CXAVZZYJNFV>G372Z7;RSW-P)`JKY:Y8#/).<+]?89J]
MX.\:V/C&UN'MXGMY[=@)()#D@'HP(Z@X(_#Z9`,U_B([S:O#9>'[Z]ETV\%J
MZ6_SLV3(-^`#@?N__'A6;!\69+J]ELK?PIJ<UW%GS((_F=,'!RH7(P2!0!N:
M5X[34O%2Z`^EW%K<_9TG<RM@H6C5]I7&01NQ^%7-?\6PZ!K>C:9):/,VIS")
M75@!&=RKDCO][]*`.<B^*<MW=W5O8>%M3O3;.4D-N"^WD@9PIQG!_*K0^(&J
M&!Y/^$(UP%650ODMDY!Y^[VQ^M`%*V^*T]Y<3V]KX2U6>>!MLT<0+-&<XPP"
MY!R#U]*V=,\=QZAXK3P^^F3VUP;=)W,K8*%HEDVE<9!&[!]Q0!F7GQ1$M]-;
M^'?#]]K:0'$LT`8(">F,*Q(.#R<=#C-=!X2\9:?XOM9I+2.6&>W*B:&4<J2.
M""."."/7CH*`)M151K]L\H_=^6,$CC@G/Z5N4`%9%YIDEK(]]I`$=R2#)!G$
M<X]QT!_VAS]<U479Z[%PE9V>S+6DZI!J]A'=VYX8#<A8$H2`0#@]P01[$'O7
M)?$;3M#U;^R;+4=4?3=2DF(T^98G<%B5#*<<#G9R2,<'.,YGT%.+A)Q9RWB&
MZ\7^$[6UE\3II'B'2C,(U2>)7*M@D<E00Q4-\Q##KGWO?%&S%O;:7XTTF9[2
M^1D0NH*LZLI*D^XY!!'(;!X&*"2YH'AZ#0_@_J4Z$/<ZAI<MU-)CG#0DJOK@
M`_F6/>N0T>RN?"_AG0?'6EH7"^9#J4.\@2(964'^0]B$.#S0!U7PLNX;_P`2
M>,[RW;?!<7B2QM@C*L\Q!P>G!JCX&_Y+/XG_`-VY_P#1Z4`4=7M];N?C;J4?
MA^\@M+_RD(EF`*[?)3(Y5OY5'K=GXIM/''A(>)M2M;UFOH_(-NH&T>8F[.$7
MV]:`*W@NS\5W>L>(?^$8U*TLMMPOVC[0H._+2;<?(W3YO3K7KOABV\06NFR)
MXDO;>\O#,2DENN%$>%P/NKSG=V[T`<7\.O\`DH'C7_K\;_T;)6%KR22?%CQ,
MD2LTC:5,$5!DD_9!@#'>@#K_`(0RV+^!8H[4K]H2:3[4!G.\G@G_`(!LY'''
ML:T=#U7PW=^,=5L]+T[9J4`?[5=I`JJYW`,-P.2=WJ.=IH`Z&_M&N[<K%((9
MQ_JY=N2GKC\*PK;6[C2KC[)K"N"3A'Z@XZE3_$.1[CTKAQ,YTJD:M_=V:_4B
M3<7?H;]M?VEYC[/<1R$C.T-R![CJ*CO]4LM,CWWEPL0*EE!ZL!C.!W/(XKNI
M-5K>SUN34K4Z<'4F[)'%_#:.Y6[URXQ$UA=W`EA:WD0Q*W)8;`Q*$ADX(S@#
M-;WBW1-`U^R2TUMUC,:O-%,'"/$JXWL">B\KG/'3/:IA"<%RS5FCT,=6HUZS
MJT'>+2_)7_$R8OA=I#7%K)?ZCJNI0VO$-O>7(>-1C&,``XX'`('`SQQ6_P")
M/#UCXKTLZ;>33)$LJN3`P#!@.!R#V/I5'(/FTNQMO"O]BS3O'9?9!8^8S`.5
M*B,<XQN.0!QR2..U1Z%H>F:?X731;61KO3U66(^:P8L&9MZM@`=2P(QQC%`%
M/PKX.TKP=+=1V%S<R/>!69;AU)PF>5PH_O\`/X4_2?!>G:/XGO\`7[>:Z:ZO
M0XD21U*#>P8X`4'J!W-`$<7AW1H_'4^OI>RG4Y`(7A,B^6#Y:_+C&=VP!L9S
M@YZ5:UKPI8Z[JVE:E=2W"3:;*)85B90K'<K?-D$D94="*`.3;X3>%=1O;B1-
M3U%Y68R.J31\9)_V.F01^!]*Z+PUX0TGP-!?SVMU<F*95>9[J12$5`QSD*,#
MYCG-`%K1?"=AH6L:IJ=K+<O/J4ADF65E*J2Q;Y<`$#+'J359?#6CP>.G\0?;
M)AJ<RA/(,B[/]7MP!MSG:A/7L3T%`&7??"C0+J^FNK6:^TXS`B2*SE"H0?O`
M`J<`^G3VK:\*>']#\-VTUCI!#R9#7$CL&E?D@%B,<`A@,`#(;OF@#H*BN(8;
MB%HKB))8SU1U#`_@:32:LP.2OM!T!+A8Q=7EJ3P$C<L#_P!]*V*F3P7I]U8>
M1<7=U,O_`"S<%4*`G)&`,'/<D$\#TK/"T8X6K[6EN<5?`TJT7&5[,Z.PT^TT
MRS2ULH$@@3HB#]3ZGW-5=4T.UU=B;AI`3:S6OR$#"R[-Q&0?F&P8/UZUM*3D
M[O<ZXQ48J,=D:=,2)8WE<$YD8,<^N`/Z4BAES`;B'8LK1L&5PP`/*D'!!['&
M#WP3@@\TVQLTL;<PHS,&EDE);'WG<N>G;+''MZT`.:W1KR.Y);?'&\8';#%2
M?_01^M34`4#IBM=Q3-.Y2&=KB*/`^5V1D(SC)7YV..N3UQ@"_0!GZ=I*Z:(8
MXKB<V\$(@AA+?*J#&,^K#&,^GODFQJ%E'J.FW5C,S+%<PO"Y0X8!@0<9[\T`
M6*IQZ>(+Z:XBF=%GD$LT>`0[!`@Y/085>!W`Z<@@%RJEG8)9SSR(YQ*<[``J
M@[F8G`XW$L<MC)`7.2,D`__9`/_M$GQ0:&]T;W-H;W`@,RXP`#A"24T$)0``
M````$``````````````````````X0DE-!"\``````$K;`0$`2````$@`````
M`````````-`"``!``@`````````````8`P``9`(````!P`,``+`$```!``\G
M`0!L;'5N`````````````#A"24T#[0``````$`!D`````0`!`&0````!``$X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24T$"@``````
M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L
M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``````
M`0`U`````0`M````!@```````3A"24T#^```````<```________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!#``
M``````(!`3A"24T$+0``````!@`!````!CA"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-)````!@``````
M```````!B@```D\````*`%4`;@!T`&D`=`!L`&4`9``M`#$````!````````
M``````````````````$``````````````D\```&*````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```&*`````%)G:'1L;VYG```"
M3P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG```!B@````!29VAT;&]N9P```D\````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``````
M```X0DE-!!0```````0````'.$))300,``````PP`````0```*````!K```!
MX```R*````P4`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I)
M)))2DDDDE*22224I))))3__0]522224I))))2DDDDE*22224I))))2DDDDE*
M22224I))))2DDDDE*22224__T?54DQ(`D\*BSJ-N386X=.^MI@W/.UO]AL.<
MY)3?25`V]:9N+L>BYLG:&6N:Z.W\Y5L_Z:G5U7&=D?9;@_&R"2&5W#;OCO19
M[JK_`/K=GJ)L)<5T)"M[C**\XY#727]TB7X-Q))5>I]0Q^F=/R.H9,^CBUNL
M>&B7$-'T6#3WO^BQ.6-I)<+_`,]OK9^S_P!N?L*H]'C?(R)MV3L]71N[9N_[
MK_R_YG]*K;/K\T=4Z?7?C"KI'5ZVOP\YSB'!SHK=1DT%FQEE&3^@OV7O9^FH
MN_F_424]>DN;ROK7<?K33]7.EXS<IX`=G9#GEK:&Z/L]K:W[W5U.K_/9^FR<
M>G_2>G7^J'U[K^L.39AY..W#RMGJT,;87BQ@_G1N<RK]+5[?9_H_^+L24]8D
MN0_YX]<R,SJN'TSI+,R[IF2RD,%X875N.0UU[O58UK-CL>O]'[_YU5*/KU]:
M<G,R,#&Z`RW-Q/Z10,IH+.VKGUMK=S_@WO24]TDN;Z/]:<W.^L=_0\K#;C/Q
ML5F18X6;W"QS,6RR@MV;/T;\M[/4;9_@E+JGUIOP?K/C=#;C-LKR,9^0;R\A
MP+695GI^GL=_W#^EO_PB2GHDEPW3/KO];.JX@S.G_5YF303M+VY36C<`"YNV
MUE;_`&[E;R?K+]<\?'9D.^K@#6U/MR2<ID5['6:<'?\`H*V7>W_2)*>N27'=
M#^N'UEZP_&NHZ&T].NM%=N8W(:0QH=LNL]*QE=C_`$OZJ73O\8=-GU:R.N]0
MQA0:LC[-3CU/WFQYKKO8&OL;3L_G'^I_HZJO424]BDN&M^NWUKP\5O5NH=`%
M72'02X7#U6,=]!]C7@.;_P!>HQ_^$]%=CT_/Q>I8-&?B/]3'R6-LK=Y.$P[]
MU[?HO8DI_]+U'(K=9CVUM^D]CFCXD0JO1S^IM:6EI&L'_-/_`$V.5Y974NF9
M1R#G8+YO@;J7&`0WZ/I/_P`'9_QGZ*W_``B9EG.,;C#CUUC='A\$$UTMU4+*
MQ<?+I=1DUMMJ?RUP_$?NN;^:]95'UEH;9]GSV.QL@<M<T@_'TS[_`/MGUZ_^
M$5P]:Z;Z=CVW!_IL=8Y@!W;6\Z.V_P!5#'GQS($9>HFN$^F?%VX4>[$:\0%:
M[U5-7!SG874OV)FY`ML>WU,%[R?5LK_2;J[?;LLLQVT_SV_])_A/?[["_67)
MP,7H6;=U+'LR\$5[<FBH`O-;R*K")?3M]-K_`%'V>JSTV?I%SF1DCK_ULP+,
M%[F'ISMQ:YKBTU_2LLWU-<VCU8]#9?9_H/\`A]G6]0RJ,3"MR,AN^EC?>T09
M!.R/TA97^=_A';%+*,XR(G'A.E>,2RRG@R8\67#D&3W(GW*_0R1EP_U?F^9\
MY9T]F!T5W6_JU]9;L;'8SUAT_*>PN#XW/Q7UAQQ_M>[]'Z?V6[UK?\)_A5L9
MG_93_BY/4NI,:,NBF[)KL:(!?C&UGJ-9/\WF4U;;&?N7^S_!J_A?4WZD]1:W
MJ-72JAO<\;22&2QSJGM]&JQV+Z>]COYO]"];M]>"]@Z/94#1D8]C?1`BOT6>
MG195[=NSVY#&L:U!8\W_`(MNFTU]&=UAY-N;U.RQUUKR7.VUV64MKWN)<[<]
MMF18_P#PEMW]1<CT#HV9D_5/]M]*);U?HV:^VC:)=94*L=UM!`]UG+WLK_PG
MZ?&_[5+T^JCIW0NF&O&J]##Q@YS::P7:N<;'-K;JYS[+;/\`/0?J_A]*P<6[
M%Z9AG`;7<?7QC$MM+*W27,?=6[?0:'?H[7_]N>HDIY7_`!<YC,_KG7\]C=C,
MPT7M:3NC>[)=MW#Z2)]5?_R@_6+X?]^8NEP^F=$Z-F'[#B-QKNI.(>ZH0'%@
MLR/<)VL;[K=NQ'Q>B]*Q,_(ZCC8[:\S+_I%PG<_6?=KY)*>%NZ5D]5_QB]7Q
M<;.NZ:]M3;#D8Y(>0*\)GHF"S]&[U-__`%M!NZ7D]*^O.#BY.==U*QV'=8,C
M()+P'4=09Z(ES_T;/3W_`/7%VF(SHHZ[=G48;J\W*+\9W4"/;:ZG8V[';[R[
M=7]E_/IKW_9;/35CJ'2NB')/6\ZAAR,2E[?M)W%S:0VWU6PW_@[[_P`W\])3
MYO\`5#$KNZ,Q[OK._H9#R/L;;:ZP=&?I]EKV/_2+NV>DWZGY5574?VOZ6-D,
M=G;VV%[MMCCO?6Y[=S-VQ5<#ZH_4W,8^.CLI=2[TWUV$%P,-=_@;KF?G?O[U
MK5=-Z/TO#9TK'QA5B9KWU&EDEI-C+++=\NW;7UUO24XO^*__`,2=7_'7?]65
MY_11;_S*IS=AMQ\/JV[(8.-KL?%:QS_S6M<_]7]W_<A>Q=-Z9T_I.(,3I]+<
M;&:2X5MF`7>YY]Q*H]`PNBUX%N+T_IQQ<#)`M++&@UW,M;Z?J;2^[^<IJ;ZE
M-WIV_P"FI24AZI]<_J_B]%?U*O(IS&N9-6,U[0^PG_!.K=[ZO^']6O\`0?X5
M:/0\QV?TG%S78WV+[16+!C$@EK7>ZN=K6?39^D^BL;*^J7U,Z2#U-W2F.-;F
M^T2Y@)<&M=Z5]GV2JNN=WJ6^G32NCHN;?17>T%K;6AX!B0'#=KM+FI*?_]/U
M5))))37R\>O(J-=U%>0SG9:`6S_::]9]'U<Z6VP7?8VT6#_16V`1^[M8:F;/
MY&Q;"2!C$FR`3Y(,0=P"AQL3&Q6N;C5,I:]V]S6`-!=`;NVM_JI\G'IRJ747
M-W5OB0"6G0[FEKV%KV.:X?2:BI)Q))LZJ``%`4/!%C8M&+5Z-#=K)<XR2XES
MR7V/>]Y<][WO=NW/4C34;FWELVL:YC7>#7ECK&_VG4UJ:2"4=]%612^B]HLJ
MM:6/8>"TZ."CBXE&(PLI!&]V][GN<][G0&[K+;7/ML=L:QGO?_-L]-&224@R
ML+'R_3-P=NI=OK<Q[ZW`D%A]]+JW_1<CI))*:M?3,*K+=F,KBYVXSN<6@OCU
M7UTEWHUV6[?TME=>^S\]6+*V6,=78T/K>"U['"00='-<T_2:Y2224UL/IV)A
M;_L["#:0;'/>^QSMH]-FZRYUC_8P;46RFJUU;K&[G4NWUGP=M=7N_P`RQZ(D
MDI2K8?3L/!+CC5[-X:TRYSH8S=Z5-?J.?Z5%6]_I45?H:O\`!L5E))2+)QJ<
MJKTK@2V0X%KG,<"#+7,MJ<RQG]AZ?'QZ<:BO'H8*Z:FAK&#@`(B22G__U/54
MDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]7U
M5))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))3__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`S`````0`X0DE-!`8```````<`"`````$!`/_A#]!H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M
M8S`S-B`T-BXR-S8W,C`L($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@
M("`@(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+R(@>&UL;G,Z>&%P34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.G1I
M9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X87`Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#
M4S,@5VEN9&]W<R(@>&%P.D-R96%T941A=&4](C(P,3$M,3(M,3A4,3`Z,C@Z
M,34K,#$Z,#`B('AA<#I-;V1I9GE$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87`Z365T861A=&%$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87!-33I$;V-U;65N=$E$/2)U=6ED.C-$,$$Q-#%$-4$R.44Q
M,3$Y0D4S041#13A",C)"-C8R(B!X87!-33I);G-T86YC94E$/2)U=6ED.C-%
M,$$Q-#%$-4$R.44Q,3$Y0D4S041#13A",C)"-C8R(B!P:&]T;W-H;W`Z0V]L
M;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV
M-BTR+C$B('!H;W1O<VAO<#I(:7-T;W)Y/2(B('1I9F8Z3W)I96YT871I;VX]
M(C$B('1I9F8Z6%)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z65)E
M<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z4F5S;VQU=&EO;E5N:70]
M(C(B('1I9F8Z3F%T:79E1&EG97-T/2(R-38L,C4W+#(U."PR-3DL,C8R+#(W
M-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y
M+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S,CLT1#,X,$(Y1#@V
M0T4P,41",C8X1CDW,#9$1$5!0C)!,R(@97AI9CI0:7AE;%A$:6UE;G-I;VX]
M(C4Y,2(@97AI9CI0:7AE;%E$:6UE;G-I;VX](C,Y-"(@97AI9CI#;VQO<E-P
M86-E/2(Q(B!E>&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L
M,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X
M-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L
M,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S
M.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L
M-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y
M.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L
M-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q
M+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X
M+#,P.T,U,D5%,30W-3<Y0C,S03E&,#`T,S<U-38T,#8Q-D1$(CX-"@D)"3QX
M87!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C<T,D4X
M-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B!S=%)E9CID;V-U;65N=$E$
M/2)U=6ED.C<T,D4X-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B\^#0H)
M"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX;7!M971A
M/@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,`
M`@$!`@$!`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*
M#0H*"PP,#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`&X",P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/W\HHHH`****`"C-9VK>,-)T`D7^J:=9$<D3W*1X_[Z
M(K-OOBYX8T[PU?ZS-KVF+I6F?\?-TLZM%&>PR,Y8]@,DY``R145*D:<'4J.R
M6K;T27=LNG3G4DH4U=O1):MOLD='FBN%T#]IGX>>)[.WFM/&OAG-RH=(I=1B
MAF`*[L&-V#`@=01D<^E=CIFLV>MV_G65W;7D6<;X95D7\P:Y\+F&%Q*OAZD9
M_P"%I_DSHQ.`Q.'=L13E#U37YHLT49HS76<@449HH`****`"BBB@`HHHH`**
M**`"BF7%Q'9V\DTTB111*7=W8*J*!DDD]`!WKQ?QS_P4?^`7PWNIK?6/C#\.
M[>ZMSB6"+7(+B:,Y`P4B9F!Y!P1G'/3F@#VNBO%?!7_!1SX!_$6[AMM'^,7P
MZN;JXQY4$FNV\$TA]`DC*Q/'3&?:O9K.\AU&TCN+>6*>"90\<D;!D=3T((X(
M/J*`)**JZKKMCH4:/?7MI9)(<*T\JQACZ#<1FJ/_``L/P_\`]!S1_P#P-C_Q
MH`V**AT_4[;5[59[2X@NH'R!)$X=#CKR.*FH`***S]3\6:5HMR(;W4]/M)B-
MP2:X2-L>N"<XH`T**Q_^%AZ!_P!!S1__``,C_P`:EO/&VBZ?<-#<:OI<$R8W
M))=1JRY&>03Z4`:=%9VG>,-(U>[6WM-5TVZG<$B.&Y1W..O`.:T:`"BBJ>K>
M(=/T'R_MU]9V7FYV>?,L>_&,XW$9QD?F*`+E%94/CW0KF9(X]:TF221@JJMW
M&68GH`,\FGW_`(RT?2KM[>ZU73;:>/&Z.6Y1'7(R,@G(X(/XT`:5%8__``L/
MP_\`]!S1_P#P,C_QH_X6'X?_`.@YH_\`X&1_XT`;%%8__"P_#_\`T'-'_P#`
MR/\`QH_X6'X?_P"@YH__`(&1_P"-`&Q16;8^--&U.Z2"VU;3+B>0X2.*Z1W;
MC/`!R:;=>.-$L;F2&?6-+AFB8JZ/=QJR$=B"<@T`:E%4-,\6:5K5R8;+4]/N
MY@N[9#<)(V/7`.<5?H`***H:GXLTK1;D0WNIZ?:3%=VR:X2-L>N"<XH`OT5E
MVOCC1+ZYCA@UC2YII6"HB7<;,Y/8`')-6-5\2:=H+(M]?V5D9<E!/.L9;'7&
MXC-`%RBL?_A8?A__`*#FC_\`@9'_`(T?\+#\/_\`0<T?_P`#(_\`&@#8HK'_
M`.%A^'_^@YH__@9'_C1_PL/P_P#]!S1__`R/_&@#8HK-A\9:/<VD]Q'JNFR0
M6VWSI%N4*1;CA=QS@9/`SUJ'_A8?A_\`Z#FC_P#@9'_C0!L45C_\+#\/_P#0
M<T?_`,#(_P#&C_A8?A__`*#FC_\`@9'_`(T`;%%8_P#PL/P__P!!S1__``,C
M_P`:/^%A^'_^@YH__@9'_C0!L452'B33CI1OQ?V1L5.#<>>OE#G'WLXZ\=>M
M5/\`A8?A_P#Z#FC_`/@9'_C0!L45#8:C;ZK:)<6L\-S!)G;)$X=&P<'!'!Y!
M'X5-0`44,P12S$!1R2>`*\?^('_!0/X&_"R\EM=?^+GP\TZ\@#&2V;7;9[A,
M=08T<N#Z#&21@9-`'L&:*\/\$_\`!2W]G[XAWD=OI7QC^'DMS,2L<,^M0VLD
MAR!A5E922<\`<GMWKVK3]1M]6LHKFTGANK:=0\<L3ATD4]""."/<4`3449HH
M`****`"BBO)/VJ_C++\/?#L6DZ;*8M5U9&S(IPUM#T+#T9CD`]L,>H%-*XFR
M7XR?M3Z7\.;B73M-C35M6C^5P&Q!;GT9AU8?W1^)!KP#Q9\<?%_Q$NC'/JEX
M$E.%M;/,4?TVKRW_``(DUR^BZ//K^IQ6L`S)*>IZ*.Y/M7T)\#_@3;SQ"9U*
M6L9VRS8Q)<-W4>B_YZY-:62)NV>0>'/@KK7B295$1C=^=@4RR?7"_P!37HGC
MS]D&_P#C;X;TG3M<EO\`3K?2$V6PL98X+<9ZN]N=RF0YY8;2>^:^B]*T>UT.
MT$%I;Q6\2_PH,9]R>Y]S5FO,S7+<+F.&EA,;#GIRW6J_)IGH9;F.)R_$1Q6$
MFX3CLU;]3X8\1_\`!+_6-.U..&QOC>VTK;1<><H$7H74KD#/]W=]:R;K_@G5
M\0_!MR;O1KN19X^DEI<+'(/H0ZM^0K[]HK\IJ>"&1.4ITJM6%W=6E'W?)7BW
M;U;?F?H5+Q<X@BE&<HR76\;W]=?^!Y'P'#XW_:#^!3H)]4U2[MHSCR]4C-PD
M@]-\RY_[Y>O5K+_@HZOPY^&_AK5_B'X>N[:?7K^[LRVEQ$I$L"P'S=CMR"9L
M<.3\IP#R!]1R1K*C(RAE88((R"/2N&^*?[.'A/XNZ#%I^I:<D$=L9&@:U`A\
MII-N\[0-C$E5SN4]*^EX.X-QV39BIXC,)U\+9KDDG=/2S3YFM.R2^9PYGQ=E
MV:4XPQ>"A3E>[G37*VK/=*W6V]R?X0?M"^"_CQIANO"GB&PU;8NZ2!&,=S"/
M]N)L.H]R,'L:[7-?!'QF_P""8NN_#[4_[?\``6HW27-FQEAETYF@NH".X0'/
MMF-L_P"S4?P?_P""DWC7X(:G'HOQ6TN;7M+1_)75[6,)=PX./G7A9,8Z'8_4
MDL>*_6*F5*I'VF#GSKMU_K[CQ:O#\*T'5RVI[1?RO22_S_#T/OO-%<[\,OBK
MX=^,?A2'6_#.K6FL:;/P)86.4;NKJ<,C#^ZP!Y'%=%FO(E%Q=I*S/FIPE"3C
M-6:Z,****DD****`"O)_VUOVP?"_[#'[/FK_`!`\5&6:VLBMO96,+`3ZI=N#
MY5O&3P"VUB3SM1';!VXKUBOQO_X.G_B%J$GB_P"$7A-9'CTN&SO]6>,.=L\S
M/%$I9?5%1\'_`*:M30'PG^VQ_P`%,/BS^W;XFN9_%WB&YM/#ID)M/#FG2-!I
M=HH.5!C!_>N/^>DNYNN"!@#P_P`-^$=6\97YM-'TS4=5NL9\FSMGGDQC.=J@
MGH#6K\&O"NF^.OB]X4T/6+PZ=I&LZQ:6-]=;U0VT$LZ)))N;@;58G)X&*_JM
M^#?P1\)?L]^`K'PQX*\/Z7X;T/3XUCBM;*`1AL`#>Y^])(<99W)9B222235-
MV`_DWU?1+WP_>FVO[.ZL;A1DQ7$31..<=&`/4'\J]B_9`_X*%_%C]A_Q1;WW
M@7Q3>V^F)('N=#O':XTF^&<LLD!.T$]-Z;9!DX89-?TL_'O]F_P-^T_X$NO#
M7CSPSI7B32KJ-DVW4`:6W)&-\,GWXG'4.A#`CK7\W'[27_!.CXG?!3X_^,?"
M6D^`_'OB'2-`U:XL[#4[;0;F>*_MED/DRAXXRA+1[2=O`)([4D[@?LS<:MX#
M_P""_?\`P3<U&*QBCT3Q%!(1'%<$22^&];ACW(=P&6@</MW@`M%(PPK@A?P`
M\?\`@/6/A;XXU?PWK]A/I>MZ#=RV-]:3#$EO-&Q5T/T(/(X/49%?J3_P;;^$
M/B7\$_VH/&N@^)/!OC3P[X:\2^'/M+2ZEH]S:6S7EM<1"(;I$5=WESW'N?SK
MJ/\`@Y`_X)VG4+.']H#PI8YFMEBL/%\$29+IQ';WQ_W?EB?V\H]F-*X'F?\`
MP;H?\%#3\)/BG+\$/%-\5\.>-;@S^'I96RMCJ9`!@!/1+A0`!T\U5`&9&-?M
M_7\A6F:E<:-J-O>6D\MM=VDJS031,4>%U(*LI'(((!!%?TI?\$D/V^;;]OK]
ME/3]7O;B(^-_#6S2O$UNN%8W`7Y+D*.B3J-XP``PD4?<IM`>X_M!?'3P_P#L
MS_!?Q)X[\477V70_#-D]Y<$8WRD<)$@)`,DCE449&6<"OY>OVL?VF/$'[7_[
M0?B;XA>)I2VH^(+HR1P!BT=A;CY8;>//\$<851W."3DDD_>W_!Q?_P`%#!\7
MOBM%\$_"U\)/#?@BX\_Q!+"WRWNJ`$>02#ADMU)!'_/5G!&8P:_.7X3_``LU
MWXW?$K0_"'AFPDU/7_$5Y'8V-M'P9)'.!D]%4<EF/"@$G`%"0'UY_P`$-_\`
M@GA_PVM^TRFO^(['S_AW\/I(K[4UE3,6IW1)-O9\\,I*[Y!R-B;3CS%-<1_P
M6N54_P""HOQ<"@`+J%J`,8Q_H-M7[[_L+?L@Z'^PY^S/X=^'VB>7.^GQ>?JE
M\$VMJ=](`9[@@\@%@`H.=J*B\[:_`G_@MC_RE'^+O_80M?\`TAMJ$!X)\"_C
M5X@_9S^+_AWQQX6O#8Z_X9O4O;23&5)'#(X_B1U+(R]U9AWK^GS]B[]J_P`/
M_MK_`+./ASXA^'66*#5X=EY9F0/)IEVGRS6[X[JW0D#<A1L885_*OFON3_@A
MG_P49/[%G[1H\,^)=1,'PX\?S1VNH&5_W.E7GW8+SGA5Y\N0\#8P8Y\M:&@/
MZ&*_('_@ZS_YH-V_Y&'_`-Q=?KZKAU#*05;D$<@U^07_``=:?\T%_P"Y@_\`
M<720'YD?L<'_`(R[^%?;_BL-(_\`2V&O>/\`@O2?^-L/Q6_[A'_IGL:\'_8Y
M_P"3N_A7_P!CAI/_`*6PU_23\6_^"<GP.^/'Q"U#Q9XQ^&GAOQ!XCU;R_M=_
M=1N99_+B2)-Q#`?+&B*..BBFP/Y;Z*_IM_X="_LT?]$<\'_]^9/_`(NOQ!_X
M+6?!7PI^S[_P4)\5^%O!>AV/ASP_966GR06-HI$4326D3N1DD\L23[FA,#Y0
MHKZ(_P""3_PM\/?&O_@H5\-/"WBO2;37/#VKWMQ'>6-R"8KA5M)W`8`@\,JG
MKU%?O+_PZ%_9H_Z(YX/_`._,G_Q=%P/PY_X(G9'_``5'^$70_P#$PNO_`$AN
M:X__`(*@X_X>*?&GCKXPU'_T>U?T*_"[_@FQ\"?@IX^TWQ3X4^&/AK0_$.D.
MTEG?6T;B6W9D9"5RQ'*LP^AK^>K_`(*@_P#*13XU?]CAJ/\`Z/:A,#Z0_P"#
M:;/_``\3O>G_`")]_P#^C[6OWUK\"O\`@VE_Y2)WO_8GW_\`Z/M:_?6DT`5^
M!7_!RSG_`(>)V73_`)$^P_\`1]U7[ZU^!7_!RU_RD3LO^Q/L/_1]U0D!\W_\
M$OL?\/%/@MQT\8:=_P"CUK[O_P"#J?\`Y'_X,'UT_5?_`$9:U\(?\$OO^4BG
MP5_['#3O_1ZU]W_\'4__`"/_`,&/^P?JO_HRUIO<#\F:*U/!-G%J/C/2+>=%
MEAGO88Y$;HRF100?PK^EG_AT+^S1_P!$<\'_`/?F3_XNFW8#^9*BOZ;?^'0O
M[-'_`$1SP?\`]^9/_BZ/^'0O[-'_`$1SP?\`]^9/_BZ5P/Q1_8TR/^"3_P"V
MAD?]"1_Z>)J^0*_J1\,_\$Y/@=X-^'WB?PII?PT\-V7ASQG]E_MNPCC<0ZE]
MEE,MOY@W9/ER$L,$<FN;_P"'0O[-'_1'/!__`'YD_P#BZ$P/YDJ*_=+_`(+&
M_P#!.3X'?`;_`()P_$;Q9X/^&GAOP_XCTK^S/LE_:Q.)8/,U2TB?:2Q'S1NZ
MGV8U^%M-`%%?NE_P1R_X)R?`[X\_\$X?ASXL\8?#3PWX@\1ZK_:?VN_NHG,L
M_EZI=Q)N(8#Y8T11[**^F_\`AT+^S1_T1SP?_P!^9/\`XNDF!^?/AD?\<K'B
M'T_M!/\`U)K>OR8K^A7_`(+#?!7PI^S[_P`$8?B9X6\%Z'8^'/#]D^F206-H
MI6*)I-;LG<C))Y8DGW-?SU41`_H]_P"""W_*)[X4]?\`F+_^GB^KU#]O3]O7
MP7_P3[^"\OBOQ9*]W?7;-;Z-HT$@6ZUBX`!V)G.U%R"\A!"`C@LRJWEW_!!J
M58?^"37PK=V5$0:N6).`!_;%]R:_%/\`X*H_MN7G[=?[7GB'Q-'=S2>%-*E;
M2O#5L6.R&RC8A90O9YFS*W?YPN2%&$D`O[;/_!57XP_MS:W=IXC\1W6C^%9'
M;[/X;TF5K?3XD.<"0`YG8`\M*6ZG`4';7S=CL*]]_P""<G[!'B#_`(*%_M#V
MO@[2ISI>CV<7V[7=6,>]=.M`P!('1I7)"HO<G)PJL1_03^S5_P`$T_@E^RCX
M;M+'PI\/]`>\M@"^KZE:1W^J7#C&7:XD4L,D9VIM0'[JKTIWL!_+SS@5[/\`
MLD?\%`?BO^Q)XEBOO`/BN^LK'S`]SHURQN-*OAGD26[';D\C>NUQDX8$U_1O
M\?\`]@GX/?M/>&[C3?&?P^\-:D+A<+>1V:6U_`<8#1W$8652!CHV#@9!'%?S
M^_\`!5/_`()U:A_P3G_:&708KNXU?P?X@@:_\/:E.`)I8@0LD,NT!?-B8@$J
M`&5D;"[BJC=P/W+_`."9_P#P4I\*_P#!1KX12ZKIT":)XMT0K%KVA/,)'M&;
M.V6-L`O`^#M;`((93R`3]*U_,?\`\$HOVIKW]D?]NKP+XBBN6@T?5;Z/0M<0
MG$<UC=.L;EO^N;%)A_M0KVR*_IPI,`HHHI`%?&_[4.N2:W\;-8#LQCLREM&I
M_A"H,C\6+'\:^R*^,OVE],DTKXW:\C@D32K.I[$.BM^F<?45=/<F19^#.C!;
M"XO2N99I/)3UP,9Q]2?_`!VOKC0=)30=%M;.,`+;QA..YQR?Q.3^-?+/PEG"
M^$H&0#=%*^?KNS_+%?5ME=I?V4,\9!CG19%/7((R*)A$EHHHJ"@HHHH`****
M``\UYM\=?V7O#/QWTN9=0M(K;4I$VB\BB4LW'`D4\2+['D=B*])HK2E5G3DI
MP=F;4,14HS52E*S78_,7QU\)/B/^P!\3/[<\)W4]K$QW-$FZ:SU&('E2I^^O
M/*G#IG(/((^ROV/_`-N'PW^U7H@MT,>C^*[2,/=Z5)("7'>2$G[\?KW7(![$
M^K^//`>E_$GPS<:3J]JMS:7`^CQ-V=#_``L.Q_ID5^8/[2?P8U#]GSXMS:UX
M2U"[M]1T.?[2D\4,EM,!U$H1U!!QG<,%6!)&03GZ"DZ>90<:BM477OZ_UZ'V
M>'G0SNFZ=9<M:*TDMGZ_UZ=3]5\CU%%?-?['O_!1+PW\>?#>G:9XCO+30_&K
MS)9-:G(CU*1N%DAZ\,>JG[I]1@U]*9KP:^'J49N%169\AC,%6PM1TJ\;-?CZ
M=T%%%%8G*%?G+_P<6_L.ZW^T?^S]H'Q`\*:?<:IK?PV>X:_L[="\UQILP0RR
M*HY8PO$C;0/N/*?X<']&J,'.::8'\@>._%?67[,/_!;#]H3]EC2K+2M-\71>
M)]`T]%C@TKQ);_VA#$BC"HLN5N%0#@*LH4#H*_6S]LW_`(()?!3]J_6;W7M+
M@O/AQXJOF:6:\T-$^QW4IZO+:-\A)/),1C+'))))-?`'QM_X-F/C7X&\Z?P;
MX@\'^.[5,[(O.;2[V3T^24&(?]_J;:`]K^"7_!TSI\WDV_Q'^%=Y;8QYM]X;
MU%9MWKMMIPF/QG.?;J?M']F'_@L=^S[^U;J=KI>A>-X=%U^\8)%I.OPG3KF1
MCT5&?]U(QZ!4D9N.G3/\_P!\>?V#_C)^S'#-<>._AOXK\/V,#;7OY+)IK!23
M@#[3'NA))]'YKR7Z4^4#^OSOUZ5F^,?!^E_$'PGJ>@ZW8V^IZ/K-K)97MI.N
MZ*YAD4JZ,/0J2*_(/_@WZ_X*H^)-6^)%G\"OB%K-UK=AJ<##PGJ%[*9+BREB
M1G-DSGEHFC4F/<<H4"#(90G['5`'\P7_``4K_8<U/]@/]J;6?!EQ]HN=`N?^
M)CX>OY!S>V$C-LR1QYB$-&_3YD)P`PK%_8J_;G\<_L'>/=9\0^![N**XUS1[
MC2;F&==\+;T/DS;3QYD,NR121SM*GY78']YO^"PO_!/N']OC]EB[M-+MX?\`
MA/?"(DU/PW.1AI7VCS;,G^[.BA1T`D6)CPI!_FWN+>2SN)(9HWBEB8HZ.I5D
M8'!!!Z$'M5+4"34M2N-9U&XO+R>6ZNKN1IIII6+O*['+,Q/)))))/4FOV<_X
M-QO^"=H\$^#Y?CWXKL=NK:]%)9>%(9D&ZULR=LUY@\AI2&C4X!\M6(RLHK\\
M/^"5G[!E[^W_`/M5:7X:FCN(O"&C;=3\37<>5\JS5A^Y5ATEF;$:]P"SX(0B
MOZ7=!T&R\+:%9:7IMK!8Z=IL$=K:VT*!(K>)%"HB@<!54``#H!1)@6Z_FJ_X
M+8_\I1_B[_V$+7_TAMJ_I5K^:K_@MC_RE'^+O_80M?\`TAMJ2`9_P2G_`&)[
M#]OCXE?$KP+/(EMK$7@&[U30+MR0EIJ,5]8")FQ_`RN\;<'"RL0,@5\W^-_!
M6K?#;QCJGA_7M/N=*UO1+J2QOK.==LMM-&Q1T8>H8$<5^A?_``:__P#)_7B_
M_LG]Y_Z<=-KV;_@XZ_X)RBYMU_:!\)61\Z(167C"WA3[Z\1P7W'<?+$_MY1X
MPQIWLP/:O^"`'_!1H_M0_`H_#+Q3?"7QU\.[6..VEE?,FKZ6,)'+SRTD)VQ.
M>X,3$DLQ'AW_``=:'_D@O_<P_P#N+K\O?V9?VBO$?[*'QS\.>/\`PK<?9]9\
M.W0G16)\NZC/RR02`=8Y$+(P]&.,$`U^@?\`P<(_M(^&_P!K;X#_`+,?Q!\*
MW!FTCQ%:Z_-Y;D>;9RC^S%EMY`.DD;AE/8E<C(()+:@?`_['/_)W?PK_`.QP
MTG_TMAK^K6OY2OV.?^3N_A7_`-CAI/\`Z6PU_5K1(`K^=K_@X/\`^4H_C7_L
M'Z7_`.D,-?T2U_.U_P`'!_\`RE'\:_\`8/TO_P!(8:2`X_\`X(G?\I1_A%_V
M$+K_`-(;FOZ5:_FJ_P"")W_*4?X1?]A"Z_\`2&YK^E6A@%?R]?\`!4'_`)2*
M?&K_`+'#4?\`T>U?U"U_+U_P5!_Y2*?&K_L<-1_]'M0@(_\`@GQ^W+JW_!/K
MX\3>/-&T+3O$5Y+I4^E&UO9GBC"RO&Y?*<Y'ECCW-?;?_$4UX_\`^B5^#_\`
MP8W/^%?!G[&'[&/C#]NWXO2^"/!$NC1:S%I\NIL=3N7@A\J-D5AN5'.[,BX&
M/7FOJS_B&E_:*_Y_?AO_`.#F?_Y'IM(#T?\`XBFO'_\`T2OP?_X,;G_"OB3_
M`(*#_MRZM_P4%^/$/CS6="T[P[>1:5!I0M;*9Y8RL3R.'R_.3YAX]A7TI_Q#
M2_M%?\_OPW_\',__`,CU\I_MG_L8^,/V$OB]%X(\;RZ-+K,NGQ:FITRY>>'R
MI&=5&YD0[LQMD8].:$D!N?\`!+[_`)2*?!7_`+'#3O\`T>M?=_\`P=3_`/(_
M_!C_`+!^J_\`HRUKX0_X)??\I%/@K_V.&G?^CUK[O_X.I_\`D?\`X,?]@_5?
M_1EK0]P/RF\.:J-"\0V%^T9E%E<QSE`<%MK!L9[9Q7[$_P#$5/X?_P"B,:Q_
MX4<?_P`CU^..D:9)K6K6ME"4$UW*L$>XX7<S`#/MDU]__P#$-+^T5_S^_#?_
M`,',_P#\CTV!]'_\14_A_P#Z(QK'_A1Q_P#R/1_Q%3^'_P#HC&L?^%''_P#(
M]?.'_$-+^T5_S^_#?_P<S_\`R/1_Q#2_M%?\_OPW_P#!S/\`_(]+0#]IOV-?
MVE(/VP/V9O"?Q)MM(ET&#Q3!+.MA)<"X>WV3R18+A5#9\O/0=:]/KQ'_`()R
M?L]Z]^RK^Q3X"^'WB=]/DU[PU:30W;6,K36Y9[F:4;695)&UQU`YS7MU2!\@
M?\%ZO^43WQ6_[A'_`*>+&OYPJ_H]_P""]7_*)[XK?]PC_P!/%C7\X55$#^CW
M_@@K_P`HGOA3_P!Q?_T\7U?7]?('_!!7_E$]\*?^XO\`^GB^KZ_J0/D#_@O5
M_P`HGOBM_P!PC_T\6-?SA5_1[_P7J_Y1/?%;_N$?^GBQK^<*JB!^Y?[(WQ-N
M/@__`,&T%QK]I,;>\M_#/B*VMI@VUH99]5OK>-U/]Y7E!'N!7X:5^T?PGT"X
M\1_\&L]W;VPW21Z-JMT1@GY(?$-Q,_3_`&4:OQ<IQ`_=S_@V6^#=GX._8K\0
M^,3$IU3QIXBEC>7;@_9K2-8XD]\2/<'/3Y\=N?T@KX4_X-T/%5MXB_X)G:-9
MP,AET'7=2L;@!LE7:47`!X&#LG3CGC!SS@?==0V`5POQK_9D^'O[2$.G1^/O
M!GASQ@FD-(UD-5L8[H6AD"[RFX';NV)G'7:/2NZK!\>_%/PQ\*M/@N_%'B/0
M?#=K=2>3#-JFH16<<KX)VJTC*"V`3@<X%`'E$/\`P3$_9XMYDDC^#'PZCDC8
M,K+HD`92.A!V\&O=:\X_X;&^$/\`T53X;_\`A2V7_P`<KT6&9+F%)(W62.0!
ME93E6!Z$'N*`'4444`%?/7[;?@%O-TWQ)!&2NW[%=$#IR6C8_7+#/^[7T+6;
MXM\+6?C7PW>:5?1F2UO8S&X'5?1A[@X(]Q33LQ-'R5\$;J6YBO[)(Y9%A`N/
ME4L$'"DG'3G;7TC\%O%2ZKH1T^5Q]HL?N@]6C)X/X'C\J\R^#?A.^^`6E_$G
M4M0C!FT&P,L#C(2X1(Y9=PXZ':GK@Y'45E?#7]JZQU=;/5-1TB"5V&[[78'R
M9?0ATSM8]CR*^<SSB[+<JQ%/#X^;BYIM.S:TTUM=J_I;NS)UHQDH-ZO4^F**
MY;P?\:/#7CC8ECJD`N'X%O.?*ESZ`-][_@.:ZFO7P>/PV+IJMA:BG%]8M-?@
M:II[!11176,****`"BBB@`KD_BY\)](^*WA6XM=1TJVU"YCB<VC/(8)$DP=H
M$H5B@)QGY6'JK=*ZRC-5&<HOFB[-&E*K*G-3@[-?UT/RW_86\.>%/%W[:UC?
MZ-JD5C'X2N+V;7/#NK/'::UH%Q!%*CH\.2)HDFP/-@+J!C<(R<5]^?LA?M2^
M'/VS?V?/#WQ#\+M+'I^MQ'S;64@S6%PA*RV\F/XD<$9Z,-K#A@:_'S_@OA\%
MC\)OVZ+GQ'HDDNG3>*]*MM>66U<Q/#<*7MI2"N"&;R0Y(ZF0GKFNM_X-M?VF
M;CP%\<O$GPFO[ESI/C.U;5=+B9LK#?VR$R!1V\RW#%CS_P`>R>]?/2XGQ%?'
M1PN+M>-XW77^5V[OKZG](<5^&-+'<+_ZV9?4<DZ=.HH/[,5S>UC?[7*W=.R:
M4&G=NY^T5%%%>^?S6%?B9_P5>_X*O_M)_LJ?M\^/?!/A;Q^=$\,:9):2Z7:?
MV#IEP$AELX)<B2:V9V^=WR2QP01VK]LZ_,K_`(.#?^"8^L_M'^'M/^+_`(!T
MV75/%/A6Q-EKFF6R;I]2L$9I$FB4<O+"6<%>6=&&.8PK-`>%?\$E_P#@M1\8
M/B]^W!X7\'_%WX@P:MX6\5)-IL$<NCZ?9)'?,F;8^9!#&^7D41`9(+2@8Z$?
MM57\@T<DEI<*Z,\4T39#`E61@>OL0:^[OV;_`/@X@^/OP)\-6>BZS)X?^(FG
MV2+''/K\$IU!4&,*;B)T,AQ_%*'8YY)IM=@/Z"+BWCO+>2&:-)8I5*.CJ&5U
M(P00>"".U?SW_P#!P3^S5X%_9M_;:LH?`MA8Z+;>)]"BUC4-*LU5+>RN6GFC
M+1QKQ$KK&K;```=Q&`<#O_B1_P`'._QG\2Z3+;>'/"'@/PS+,NW[6T-Q?3PG
MGYD#R"//3[R,..ASQ^?OQ?\`C%XH^/OQ$U/Q;XRUN^\0^(M7D\R[OKI@7D(&
M````JJH``50%4`````4D@/2/^":JW[?\%"?@F--,GVC_`(3;22VP@'R?M<?G
M=>WE;\^V:_J.K\5?^#=G_@F_K7B/XJ6WQY\6:;<:?X=\/QRQ^%X[B)D;5;J1
M&C:Z4$?-#&C.`PX,A&#F,U^U5#`*_D;^(?\`R/\`KG_80N/_`$8U?UR5_(W\
M0_\`D?\`7?\`L(7'_HQJ<6!^IW_!JQ_R/_QGZ?\`(/TK_P!&W5?LM7XT_P#!
MJQ_R/_QG_P"P?I7_`*,NJ_9:DP"OYJO^"V/_`"E'^+O_`&$+7_TAMJ_I5K^:
MK_@MC_RE'^+O_80M?_2&VH0'O'_!K_\`\G]>+_\`LG]Y_P"G'3:_<WQ7X5TW
MQUX7U'1-8LK?4M(U>UDLKVTG0/%<PR*4>-@>JLI((]#7X9?\&P'_`"?SXO\`
M^R?WG_IQTVOW=HEN!_,;_P`%/?V#M3_X)_\`[46J>%G2>?POJ9;4?#=^_/VJ
MR9CA&;O+$?W;],E0V,.N?!KKQ=J=]X3L="FO9Y-(TR[N+ZUM"V8X)ITA2:11
MV+K;P`_]<UK^D[_@K!^P#8_\%`/V7+_1+>&&/QKX=$FI>&+ML*4N@OS6[,>D
M4ZC8W8,(W.=@%?S5Z[H=[X7UN]TS4K6>QU'3IWMKJVG0QRV\J,5=&4\AE8$$
M'H0:J+`[S]CG_D[OX5_]CAI/_I;#7]6M?RE?L<_\G=_"O_L<-)_]+8:_JUI2
M8!7\[7_!P?\`\I1_&O\`V#]+_P#2&&OZ):_G:_X.#_\`E*/XU_[!^E_^D,-)
M`<?_`,$3O^4H_P`(O^PA=?\`I#<U_2K7\U7_``1._P"4H_PB_P"PA=?^D-S7
M]*M#`*_EZ_X*@_\`*13XU?\`8X:C_P"CVK^H6OY>O^"H/_*13XU?]CAJ/_H]
MJ$!](?\`!M+_`,I%+W_L3[__`-'VM?OK7X%?\&TO_*12]_[$^_\`_1]K7[ZT
M2W`*_`K_`(.6O^4BEE_V)]A_Z/NJ_?6OP*_X.6O^4BEE_P!B?8?^C[JB.X'S
M?_P2^_Y2*?!7_L<-._\`1ZU]W_\`!U/_`,C_`/!C_L'ZK_Z,M:^$/^"7W_*1
M3X*_]CAIW_H]:^[_`/@ZG_Y'_P"#'_8/U7_T9:TV]0/RQ^'G_(_Z'_V$+?\`
M]&+7]<E?R$65[+IUY#<0.T<T#B2-QU5@<@_G7T5_P]X_:7_Z+'XP_P"_T?\`
M\31(#^FVBOYDO^'O'[2__18_&'_?Z/\`^)H_X>\?M+_]%C\8?]_H_P#XFE8#
M^FVBOR/_`.#>W]M_XL_M0_M,>-=(^(/CO7?%>F:?X8-Y;6]](K)#-]K@3>,`
M<[68?C7ZX4-`?('_``7J_P"43WQ6_P"X1_Z>+&OYPJ_H]_X+T_\`*)[XK?\`
M<(_]/%C7\X5.+`_H]_X(*_\`*)[X4_\`<7_]/%]7U_7R!_P06_Y1/?"G_N+_
M`/IXOJ^OZD#Y`_X+U?\`*)[XK?\`<(_]/%C7\X5?T>_\%Z?^43WQ6_[A'_IX
ML:_G"JHL#^A[_@C9\.;#XP?\$3O!GA+559M+\4:7X@TF[``)\J?4]0B?&>^U
MC7X#_&;X3:S\"/BQXC\&>((#;:SX8U";3;M,':7C<KN7/5&`#*>ZL#WK^A?_
M`((+?\HGOA3_`-Q?_P!/%]7A_P#P71_X)"7_`.U#!+\7/AI8_:?'>EV@BUG1
MH8\R^(+>,822+'WKF-?EV]9$"J/F55=)V`^4O^#>#_@H+I/[-7QAUGX9^,=2
MBTWPQ\098IM.N[APEO8ZH@V!7)X59TVIN/1HHAP"2/W<K^0F_L)]+OI[:YAF
MMKFV=HI894*21.I(96!Y!!!!!Y!KZI_9O_X+6_M$?LR>&[30]*\:#7M"L$6.
MVL/$%HFH+`B\!%E;$P0``!1)M`&`!3:`_I-K\,/^#DO]L[3/C5\??#WPP\.W
ML-]IWPX2>35IH6#1MJ4VT-#D<$PQH`<'AY9%(RE>-_';_@O+^TA\=?#-QH[^
M++'PEI]XACN!X<L193R+W`G)>9/K&Z_E7QP6>XF+,7DDD;))Y9B3^I)H2`[;
M]FCX*WW[1O[07@SP+IR2-=>*M7M].W)UBC>0"20^R1[G)[!37]7]E9Q:=9PV
M\"+%#`@CC0=%4#`'X"OR\_X("?\`!*75?@.@^-?Q&TR33O$VJ6;0>&M*N$*S
MZ7;2KB2ZE4\I+*AVJAY6-GW<OA?U(I-@%%%%(`HHHH`\K_;6\0?\([^R]XNF
M!.^>V2T51]YS+*D>!Z\,?PK\_O!7C>^^&.L&SU2VN[:VGVO+#-&R21A@"L@4
MC/((/N,>U?JE+`LI7>BOM8,,C.#Z_6O,OVEOV5]`_:1\/^7?(+#6K5"MEJ<2
M`RP]PC_WX\_PGIDD$$FOS+CW@>OG4EBJ%3WH124&M'JV_>OHW=6TMIJ]=/(S
M#`U:DU6I2LTM%W/E>PUBWO8X+J(Q75L^'&&.R1<],CD9Z<<U]:?`;XN>'?&N
M@0:=IC&PO+5,-83SM)(!W*,Q)=??J.X%?GUX[\(^-/V1?%K:7X@L9'TZ=R89
M4):UNP/XXGQPWJIP1W'0UTWA7XB6NOQQ7NE7CQSPD.-CE)H&'0G'(/H1^!K\
M=X<SK&\+XZ?/2NGI*+5I?)VNOR?;9KDP^9<LG&:M);I_H?I'FBOE7X5?MRW_
M`(>$5EXIMWU2U7Y1>0@+<H/]I>%?]#]:^A?A_P#%[PY\3[59-$U6UO'V[F@W
M;)X_]Z,X8?7&/>OZ(R+B_+,VBOJU2T_Y9:2^[KZJZ/8H8RE5TB]>W4Z6BBC-
M?3G4%%&:*`"HYED:%Q$Z)(5.QF4LJG'!(!&1[9'X4AU"W%\+4SPBZ:,RB'>/
M,*`@%MO7&2!GIDUYM^U/^U7X7_9.^'-SKNOW*R7;HPT_3(G'VG49>R(.R@D;
MG/"CU.`>C#82MB*L:%"+E*6B2W9Q8[,L-@L//%XJHH4X*\FWHO7_`"Z['Y`?
M\%=_V@]?^/7QKL]%\6>&H/#7B7P!:3Z-J4<$AD@O)#(76XA+?,(I(RCJK9(#
M?>;.:\!_X)\^*)OAG^W-\)=7@D>$1^*;"VE=<Y$,\RP2CCKF.1QCO7U)^V.]
M[^WI^SK:_&33](CD^('AF]_X1[QA8:;"Q,MO-(387:QC+;0&,!/+,P'9:\C_
M`&8/V!_CW>?%#PQXHT#X2>(;L^'M4M=5B368?[*M;KR9DE"E[AH\HVW!*G."
M<<U^8\1Y/F&6YY/"8F+<X26J5[K2ST6NG4_T3\,.->$N(_#&AC\!5IT:%2E.
M'+*:BHS:?/&\Y:>\[I-NR:3/Z`\T5@?#/7==\2^"+"]\2^'U\,:W.F;K34OD
MODMGST$R`!QWS@?2M^OT2,KI-'^?U:E*E4E3E9M-K1IK3LTVFNS3:?1A1^=%
M%49'R;^V-_P1;^!G[96JW6M:GH-QX4\5799Y=9\.R):37+G^.:(JT4I)Y+%-
MY_O#K7Q1XZ_X-6[^.ZFD\,_&2TFA;F*'4_#[1.G(X:2.=@W&3D(.PQWK]B:*
M:8'XS^%_^#5SQ'<W*?VU\8M$LH0WS?8M`EN6*X[;YHQDGCVZ\]*^I?V7/^#>
M'X$_`'6;75_$<>K_`!,U>U99$76V1-.1P<AA:Q@!Q_LS-(OM7WG11<"*RLX=
M.LXK>WABM[>W01Q11J$2-0,!5`X``&`!TJ6BBD`5^:>M_P#!L1\)-=UF\OI/
M'_Q&22\F>=E5K+:I9BQ`_<=.:_2RBG<#Y:_X)U_\$I?!O_!-W6?%5]X5\1^)
MM=D\60VT%RNJF`K"(6D92GEQKR?,.<YZ"OJ6BBD`5\&_M8?\$`OAM^US^T+X
MF^(VM>,_'&F:IXHGCGGMK(VHMXBD,<0"[XF;&(P>2>2:^\J*`/CW_@GW_P`$
M:/`G_!._XRZGXV\,>*?%NMZAJFBRZ))!JAMS"D4D\$Q<>7&IW!K=1UQACQTK
M["HHH`*^&_VR/^""GPI_;'^/6J?$&^UOQ3X6U77(XSJ%OI!MUM[J=1M,Y$D;
M$.RA0V#@E=W4DG[DHH`_.;X7_P#!M?\`"KX5?$SPYXHLO'?Q!N;OPWJ=MJD$
M4S6?ERO!*LJJV(0=I*`'!!QFOT9HHIW`*^(/VUO^"%7P\_;A_:%U;XC>(/%_
MC32-4U>&W@DMM.-L+=!#"L2D;XF;)"`G)ZU]OT4@/@W]D_\`X(!?#;]D;]H7
MPS\1M%\9^.-3U3PO/)/!;7IM3;REX9(B&V1*V,2$\$<@5]Y4447`*_/G]H/_
M`(-V?AA^T3\;_%?CO5/&_CRQU'Q;J<^J7%O:FT\F%Y7+%4W0EMH)XR2:_0:B
MBX'QG^P7_P`$4_`7_!/[XX2^._#7BOQ?K6HS:9-I9M]3-L8`DKQN6_=QJVX&
M,8YQR:^S*,T4`%?&?[>G_!%/P%_P4!^.$7COQ+XK\7Z+J,.F0Z6+?3#;"`I$
M\CAOWD;-N)D.><<"OLRB@#\^?V?/^#=GX8?L[?&_PIX[TOQOX\OM1\):G!JE
MO;W1M/)F>)PP5]L(;:2.<$&O8?\`@HI_P2E\&_\`!2+6?"M]XJ\1^)M"D\)P
MW,%LNE&`+,)FC9B_F1MR/+&,8ZFOJ6BG<#\R?^(7+X0_]%"^)'_?5E_\8H_X
MA<OA#_T4+XD?]]67_P`8K]-LT47`_,G_`(A<OA#_`-%"^)'_`'U9?_&*/^(7
M+X0_]%"^)'_?5E_\8K]-J*+@?(__``3U_P""/G@C_@G1\3-;\4>%_$_BO7+O
M7-,_LN6+5#;F*-/-27<OEQJ=V8P.3C!-?7%%&:0'F/[8W[+FD?MH_LX>(_AI
MKVHZEI6D^)?LWGW5AL%Q%Y%U#<KMWJR\M"H.0>">^#7PO_Q"Y?"'_HH7Q(_[
MZLO_`(Q7Z;9HIW`\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NI
MKEMVQ57AIF`P!P!WR:].HHI`>8_MC?LN:1^VC^SAXC^&FO:CJ6E:3XE^S>?=
M6&P7$7D74-RNW>K+RT*@Y!X)[X-?"_\`Q"Y?"'_HH7Q(_P"^K+_XQ7Z;447`
M\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NIKEMVQ57AIF`P!P!
MWR:].HHH`^9OVS?^"1_P3_;@O9]5\4>')-(\53+M/B#0Y19W\F!@&7AHICT&
M949@``"!7PM\0_\`@U<F%Y++X3^,436[$^7;ZMH!#QC(P#+%-AN,\B,=!QSQ
M^P5%-,#\;?!G_!JWK<]VA\0_&+2K2W5_F33M`DN'=>.`TDR!2>><'&!US@?:
MO[&7_!$KX'_L::S::]::1=^,O%MDPDAUCQ`Z7#6D@_C@A55BC(."&*LZXX?K
M7U[10V`?G11FBD`4444`%%%%`!1110!C^-_`6C?$GPY/I&O:;::KIMR,/!.F
MY<XP&'=6&>&!!'8BOB?]H'_@EQKOA#4)=<^%VHRWL29?^R[F81W47?$4IPL@
M[;7VG`ZN37WA17A9UPW@,TARXJ%VMI+22^?Z.Z\CCQ>`HXA6J+7NMS\BI/B]
MJO@76I-&\8Z1?:;J-J=DOF0&&5/=HVQ^8X]!73Z'XYM-6*7.E:@CRQG<K0R%
M9(SZX^\IK](_BK\#_"7QOT8V'BK0-.UJ``A&GCQ+#GO'(,.A]U(KY'^,7_!&
M33KVXEO?A_XKNM'GSNCL]44S1`YZ+,F'11[JY]Z_(,U\+<71DZF!ESK[G]ST
M^Y_(^;Q638J&M)\Z^Y_Y&!X._;1^('@-4C36!JMM'TAU&,7&?^!\2?\`CU>D
M>'_^"GTUN%36/"<4I'WI;.]*#\$=3_Z%7RC\0/V0_P!H7X*N_F>'+WQ+8QG"
MS:;C4Q)COM3]^!_O**\EUGX[ZWX3U!K/7?#DMG>)]^&426LB_P#`7!(KSZ.8
M\397^[=2:2Z25_NYT_P/'J9CF.&TO)>J_P`S]+;7_@J%X)\K-UH?BF)_2**"
M0?F95_E71_"']N[P[\<?B-9>&]`T/Q'Y]RCRR3W4<,<5NB*26;;(YQT`]2P'
MO7Y0S?M-V94EM+NE;T$JD?R%>R_L2_\`!2/P-^S]XCUV7Q'H?B**76;=+2#4
MK`0SO8IDELQN5R"VTD@G[@^4U]-DG%^;U\93IXR<84[^\^5;?+OMMH:8/B/&
MSKQC6DE"^KLNG3Y['H/[7?[4^OV_[9FH^(/"6KRZ?)X6A;0K.6,+(CJN1/E&
M!1P92Y&01\B'J!CYD^-/CBY\57USKGBO6+S5]1G',MU*9II`,X5<GA1G@#"C
MVKVB+]G+1/V@;MYOA'\7_"'BBXNR7_LK52VEZT6)^Z(YL^:V>K`*,_45X)\?
M?V7O'?P:OV/B_P`/:SI<;L$-[<Q-+;'G'$R;D;'HI)K^^N$L5D.*P]/^S:\)
MRC%1TLI-+UL][OU9_%O%^6<73QU;$Y[2J1H5*DJGNR<Z:<NTHMTTU&ROO96/
M(O`7[8GQ(_9B^(.K>(OA]K;^'+O4[)M.D'V>&Z3R2ZN#LE5D+AE!#;<C)`X)
M%?JG_P`$=?AA\:O$/AS4OBS\;?&/B[5=0\4VX@\/Z'J-VZ6UG9EE=KLVHQ&D
MDI"A/D#+&I/23`SOV'?^"-?@CP0^C>.O&VHZ9X_U*2..^TZVM1OT:$,`Z2Y/
M-SQ@@L%3G[AX-?>1SZ5^=\=<58'%2EAL!33D])5''5V^RFU>W=_):']7>%W!
M689=AZ=;,)N,(J\*2E=*_P!J23Y;]EKKJ]=!:***_+S]H"OSR_X+.V%MXO\`
MVO/V3_"FL>(]8\.>%?$^J:Y;:S+8ZL^F;X@NGD%I58`8).">FX^M?H;7YR?\
M%L=*\%ZY^V?^R#:?$1]$C\$W&K:\NL-J]PEO8B#9IN?-D=E55SCDD4`><?M^
M?`/P!^Q7\%D\??!#X[>/8?BA8ZG8V^@Z)!XV.L#Q!))=1H\!M<L\G[MV<KRI
M";2IW5^J'@V[U'4/"&DW&KVZ6FJSV<,E[`ARL,Y0&1![!LC\*_+'_@H=\.OV
M(/AY^R]XA\1?#/Q!\/-(^)FC1K/X6N?`WBA9]4CU`.#%A+:=CL)X9V7"C)!#
M`&OTA_93OO%6I_LQ_#RY\<QRQ>,[CPWI\FMK*-LJWAMHS-O&!A]^[<!P&R!Q
M3N!W]%%%(`KY,_X+E^(=0\*?\$M?BCJ&EWUYIM];_P!D^5<6LS0S1YU>R4[6
M4@C*D@X/()%?6=?('_!>K_E$]\5O^X1_Z>+&@#ZI\`2-+X$T1W9G=["`DDY)
M/EKS6M6/\/?^1`T/_L'V_P#Z+6MB@`HHHH`^;?\`@JS^UUK'[&O[(FH:]X6@
M2?QIXBO[?PWX<5E5PM]<EMK[6X8I&DKJI!!95!&W->5^"?\`@AWX.\2>`H+W
MXG^-OB9XN^)VHVZ3:GXD7Q1<Q/;79&2;9<[0B,<)YBMPHX'0=+_P6\^!GB7X
MQ_L70:IX1T^;6-?^&OB2Q\9V^G1(9)+U;42I(@4<MMCG=]HY(C(&3@'T3X,_
M\%//@;\9O@S9^-8/B3X/T6REMEFO;35=7@M+S2Y"N6AFC=@P=3D<`AL94L""
M0#RC_@F9\:O'7@?]H#XK?LV_$KQ#=^,=9^%OV?4/#_B&[RUWJND7"JR?:&)R
MTD8DARQ+',CJ6.P$_:E?!'_!-#6[K]KO]O?XX_M&Z?:W=I\/]5M;7P=X5FN(
MFB.KQ6_EF:Y"L`P7?"I&0/\`7%3\R-7WO0`4444`%?$'_!+#Q3JFO_MD?MAV
MU_J5_?6VF^/(XK2*>X>1+5-UW\L88D(.!P,#@5]OU^;W_!.[]HWX>?`G]MW]
ML2'QQX\\&>#9=2\?*]HFN:W;:<UTJ/=AC&)G7>%++DC.,CUI@?I#17%?"S]I
M7X<_'/4+NT\$>/\`P3XQN[",2W,.AZY:ZA);H3@,ZPNQ52>,G`S7:T@"BBB@
M#-\9>+++P%X0U77=2E\C3M%LYK^ZD_YYQ1(7=OP52:_.C]CG]D_4?^"MGA&Y
M^.OQU\1^,)M"\4:A<_\`"(^#=,UF:PTS2+"*5X5=A$59I2RN-P*E@H8E@X"_
MH3\6?`<?Q3^%GB;PQ+*8(O$>E76EO*!GRUGA>(M^`;-?#W_!'O\`:X\+?`_X
M!+\`OBAK6D^`?B;\)KZ[TNZT_6KI+%=0@:X>:*XMWE*K*A67`VG)"A\;64D`
MH6_AS7?^"2'[;GPN\,Z)XL\2^)?@=\;=0/AU=%UV_:^E\,ZH2JP-;2-R(W:1
M!M[C?NW,$(_1"OSO_:@^-6C_`/!0_P#X*)?`GX;?"[5+7Q3HGPD\1Q^/?%VN
MZ;(MQIUBUJR-;P+.N4=V8,A"DX,JC.5?;^B%`!1110`5\2_\%&/BCXZ^-7[5
M_P`./V8OA]XEO_!!\9Z;-XD\7^(;`F._LM(C=T6*W<'*-*\,J$CG)C!PA<'[
M:KX`_;O\1K^Q#_P5'^%_[0>NVMROPU\1^'9?`?B34X8FE7193,\T$\H`)",6
MC'R_PP28!;`8`O?%C_@B1X=\$?#2[UCX*>+_`(C^$/BMH=NUUH^K-XFGF&I7
M*#<(;E781[)2-I*A5!;)#*"A^NOV;=0\;ZI\"/"LWQ)T^TTOQX=/C37(+:6.
M6'[4ORNZ&,E-KXWX4D+OQVKXJ_X*-P?LB^/_``UK'Q4\1^,+3Q9XLO-+6WT7
M3_#7C29[G6)@C+;10VUK-R6<@%]N!G+&O4_^"$NHW&J_\$J?A9<75Q-<W$G]
MK;I)7+NV-8O0,D\G@`?A0!]<T444`%>>?M=7DVG?LH?$^YMYI;>X@\):K)')
M&Q1XV%G*0RD<@@\@BO0Z\X_;&_Y-$^*G_8GZM_Z134(#S_\`X).ZS>>(?^"<
MOPBO;^ZN;Z\N=!1Y9[B5I993O?EF8DD^YKZ'KYP_X)"_\HTO@Y_V+Z?^C'KZ
M/H`****`//?VL/CU;?LO?LV>-_B#=0"[3PGI$]_';EBHN9E7$41(Z!Y"BY[;
MLU\:?LJ?\$PHOVS?@OHOQ7_:)\5^.O%WC;X@6::S#80:Y<:?I_AZVN!YD$-O
M#"RA#Y1C9E/`8[=N06;ZG_X*'?`C4/VF?V)/B7X'TF,2ZOKFBRC3XB=HFN8B
M)H8\Y&-TD:KD\#//%>._\$S?^"C7PR\??LB>$-&\1^,/#G@WQEX$TJ#P_P"(
M-&UV_BTR[M+BSC6!I/+F924;8&R,A22IPRD`N!M?L'?L\?%[]DCXW>.?`VM:
M]JWC?X(FWBOO!NLZUJ276IZ;+E1)8."?,*`,V#M"?N00$+E:^KJ^4?V/_P!N
MK7?VS/VS/B7:>$8],U'X%>!]/BTZSUZ.U</JVLLT;/Y,Y;;)"B"4$*O>)L[7
M7=]74`%%%%`!7Y5Z_J7@;]KC_@IC\9?"/[2WQ'UCPEIG@N[M[+P/X4GU^30=
M+O+4JY:Z\P,@DF<>4X^8,1+CYU4*GZJ5\$I^T)\$?VO_`(\?$CX4_M,>#/AO
MX=\:^`];ELM#;7'2W?5M*/,$]M=2['#./G,:.,JZ$`X;#0':_L7_`+(OC?\`
M9$_:DU:U\'>*K[Q7^SAXDT-;NPM]4UK^T)]#U,2?<MR22860,21U\Q<Y*%C]
M@U^7?[,7A;P'^SG_`,%@_"/@G]FKQ5=ZO\./$/A_4+_QWH>G:NVL:-H[1PR?
M9YA*7<+(9A;J=S,R[PN<2;1^HE(`HHHH`****`"BBB@!"X!QS33,!GC-(V<'
MUJ"0D+R:`)C=*.H-,.H(O4&JD^XIE2`?>L+6FU((WV::W0]1N4F@#ICJD8[$
M_C5+7++3/$UF;;4K"SU"W/)BN85E3KZ,"*\F\63^/\L-.U?0X2.GFV[L/TKE
M;*;XQ"]S-XC\(-`3PJ6$P8#ZEJ;A=69+:>AZ+K/[(OP@\1S^;>?#+P+)+G)=
M=$MD9N,<E4!/`[UEV_[`_P`$(IY95^&'@]GF.6#V*.HY[*V0OX`5<\*S>,"%
M%_J6E3-CGRH64?K7<:6;LJOG21,?]D$5R2R_#-W=./W+_(Q>%H2U<%]R,OP5
M^SS\._AW<1R^'_`G@_1)XB"LMCH]O;R`@#G<J`D\#G.>*[.Y@AO[>2">*.:&
M52KQNH97!Z@@]156(G`R>:G0G`]*WITXP5H*WIH:QIQBN5))$/AWPWIWA+28
MM.TFPLM+T^`L8[:T@6"&,LQ9B$4`#+,S'`Y))ZFK],7[PI]:2DVVV[MCA!1B
MHQ5D@HHHI%!7'_%;]GKP!\>/L'_"<^!_!_C/^RO,^Q?V[HUMJ/V/S-OF>7YR
M-LW;$W;<9V+GH*["B@#S#PI^Q)\&/`?B&TU?0_A%\,-%U:PD$MM>V/A:QM[B
MV<=&21(@RL/4$&O3^E%%`!1110`5C^/?AYH'Q4\)W>@>*-"T?Q)H5_L^U:=J
MEE'>6EQL=9$WQ2!D;:ZJPR.&4$<@5L44`,M[:.TMXX88TBBB4(B(H544#```
MZ`#M3Z**`"BBB@`&>>*\4\:?\$W_`("_$/QO)XDUKX1^`]0UF>0RS7$FE1#[
M2YZM(@`61CW+@DU[710!4T'0+#PKHMKINEV5IING6,:PVUK:PK#!;HHP$1%`
M"J!T`&!5NBB@`HHHH`*\N\4?L/\`P6\;^([W6-;^$'PNUC5]3F:XO+Z]\*V%
MQ<W4K'+222/$6=B>22237J-%`'$_"S]FKX<_`S4+J[\$^`/!/@ZZOXQ#<S:'
MH=KI\EP@.0KM"BEE!YP<C-=M110`4444`%>;?'7]COX6?M-2V\OC_P``^%_%
M5S:+LANKZQ1[F%,YV+,`)`N>=H;!]*])HH`Y+X._`;P5^SYX:;1_`WA3P_X2
MTR1_,DM]+L8[99GQC>^P`NV.-S9..]=;110`4444`%4/$WA?3?&F@7>DZSIU
MAJ^E:A&8;JSO($N+>Y0]4>-P593Z$$5?HH`\=^&7_!/GX(?!GQROB7PO\*_!
M.BZ]$WF0WMOI<?FVK?WH<@^4>V8]IQ7IG@CP'H?PS\,V^B>&]%TGP]HUFTC0
M6&FVD=I:PF21I'*QQ@*I9W=C@<LQ)Y)-:U%`!1110`56UG1K/Q%I%WIVHVEM
M?V%_"]O<VUQ$LL-Q$ZE7C=&R&5E)!!!!!(-6:*`,SPAX-TCX>^&K+1=`TK3=
M#T;3H_)M+#3[9+:UM4SG:D:`*JY)X``YK3HHH`****`"O(OC!^P/\%OC]XM&
MO>,OACX.U_6R07O[C3D%Q/MZ"1U`,@`&`')&.*]=HH`QO`/P[T#X5^%;70O#
M&B:3X>T6Q&VWL--M$M;:$$Y.V-`%&3R>.36S110`4444`%>=_'/]DCX8_M,Q
MVX\?^`_"_BR6T&V"?4+!)+B!<YVI+CS%4GD@,`:]$HH`XGX)_LW>`/V;]#FT
HWP%X.\.^$;2Z*M<+IEC';M=%1A6E91ND8#/+DGFNVHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
